161 related articles for article (PubMed ID: 34143707)
1. The design and discovery of phospholipase A
Batsika CS; Gerogiannopoulou AD; Mantzourani C; Vasilakaki S; Kokotos G
Expert Opin Drug Discov; 2021 Nov; 16(11):1287-1305. PubMed ID: 34143707
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of phospholipase A
Kokotou MG; Limnios D; Nikolaou A; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Feb; 27(2):217-225. PubMed ID: 27718763
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A
Nikolaou A; Kokotou MG; Vasilakaki S; Kokotos G
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Jun; 1864(6):941-956. PubMed ID: 30905350
[TBL] [Abstract][Full Text] [Related]
4. Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Yarla NS; Bishayee A; Vadlakonda L; Chintala R; Duddukuri GR; Reddanna P; Dowluru KS
Curr Drug Targets; 2016; 17(16):1940-1962. PubMed ID: 26212262
[TBL] [Abstract][Full Text] [Related]
5. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A
Zhuo S; Yuan C
Sci Rep; 2020 Oct; 10(1):17232. PubMed ID: 33057060
[TBL] [Abstract][Full Text] [Related]
6. On the present and future role of Lp-PLA
Fras Z; Tršan J; Banach M
Arch Med Sci; 2021; 17(4):954-964. PubMed ID: 34336025
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A
Mouchlis VD; Morisseau C; Hammock BD; Li S; McCammon JA; Dennis EA
Bioorg Med Chem; 2016 Oct; 24(20):4801-4811. PubMed ID: 27320659
[TBL] [Abstract][Full Text] [Related]
8. Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.
Mouchlis VD; Limnios D; Kokotou MG; Barbayianni E; Kokotos G; McCammon JA; Dennis EA
J Med Chem; 2016 May; 59(9):4403-14. PubMed ID: 27087127
[TBL] [Abstract][Full Text] [Related]
9. Lipidomics of phospholipase A
Murawska GM; Armando AM; Dennis EA
J Lipid Res; 2024 May; 65(7):100571. PubMed ID: 38795860
[TBL] [Abstract][Full Text] [Related]
10. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
Daida H; Iwase T; Yagi S; Ando H; Nakajima H
Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
[TBL] [Abstract][Full Text] [Related]
11. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2: The story continues.
Huang F; Wang K; Shen J
Med Res Rev; 2020 Jan; 40(1):79-134. PubMed ID: 31140638
[TBL] [Abstract][Full Text] [Related]
13. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
14. Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications.
Ong WY; Go ML; Wang DY; Cheah IK; Halliwell B
Mol Neurobiol; 2021 Jan; 58(1):106-117. PubMed ID: 32897518
[TBL] [Abstract][Full Text] [Related]
15. The synthetic varespladib molecule is a multi-functional inhibitor for PLA
Salvador GHM; Borges RJ; Lomonte B; Lewin MR; Fontes MRM
Biochim Biophys Acta Gen Subj; 2021 Jul; 1865(7):129913. PubMed ID: 33865953
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D
PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643
[TBL] [Abstract][Full Text] [Related]
17. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.
Lewin M; Samuel S; Merkel J; Bickler P
Toxins (Basel); 2016 Aug; 8(9):. PubMed ID: 27571102
[TBL] [Abstract][Full Text] [Related]
18. Phospholipase A2 inhibitors in development.
Tibes U; Friebe WG
Expert Opin Investig Drugs; 1997 Mar; 6(3):279-98. PubMed ID: 15989628
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2.
Six DA; Barbayianni E; Loukas V; Constantinou-Kokotou V; Hadjipavlou-Litina D; Stephens D; Wong AC; Magrioti V; Moutevelis-Minakakis P; Baker SF; Dennis EA; Kokotos G
J Med Chem; 2007 Aug; 50(17):4222-35. PubMed ID: 17672443
[TBL] [Abstract][Full Text] [Related]
20. [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].
Chen J; Cai HW; Miao J; Xu XM; Mao W
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):703-8. PubMed ID: 27491230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
